General Motors Q4 Adjusted Earnings, Revenue Down; 2024 Earnings Guidance Tops Street View

General Motors (GM) reported Q4 adjusted earnings Tuesday of $1.24 per diluted share, down from $2.12 a year earlier. Analysts polled by Capital IQ expected $1.14. Revenue for the quarter ended Dec. 31 was $42.98 billion, down from $43.11 billion a year earlier. Analysts surveyed by Capital IQ expected $39.47 billion. For 2024, the company expects adjusted earnings of $8.50 to $9.50 per diluted share. Analysts polled by Capital IQ expect $7.76. GM shares rose more than 7% in premarket trading.

General Motors Q4 Adjusted Earnings, Revenue Down; 2024 Earnings Guidance Tops Street View Read Post »

Truist Financial (NYSE:TFC) Stock Analyst Ratings

Truist Financial (NYSE:TFC) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/30/2024 12.57% Morgan Stanley $38 → $43 Maintains Equal-Weight 01/19/2024 -0.52% Piper Sandler $37 → $38 Maintains Neutral 01/19/2024 9.95% RBC Capital $40 → $42 Maintains Outperform 01/19/2024 15.18% Keefe, Bruyette & Woods $42 → $44 Maintains Outperform 01/05/2024 7.33% Raymond James $34 → $41 Maintains Outperform 01/04/2024 12.57% B of A Securities → $43 Upgrades Neutral → Buy 01/02/2024 9.95% Barclays $40 → $42 Maintains Equal-Weight 12/14/2023 5.89% Odeon Capital → $40.45 Upgrades Hold → Buy 12/08/2023 -10.99% Piper Sandler $31 → $34 Maintains Neutral 12/04/2023 -0.52% Morgan Stanley $40 → $38 Maintains Equal-Weight 11/20/2023 -13.61% Evercore ISI Group $31 → $33 Maintains In-Line 10/20/2023 -18.85% Piper Sandler $32 → $31 Maintains Neutral 10/05/2023 -10.99% Raymond James $36 → $34 Maintains Outperform 10/03/2023 4.71% Morgan Stanley $41 → $40 Maintains

Truist Financial (NYSE:TFC) Stock Analyst Ratings Read Post »

MSCI’s Q4 Adjusted Earnings, Operating Revenue Increase

MSCI (MSCI) reported Q4 adjusted earnings Tuesday of $3.68 per share, up from $2.84 a year earlier. Analysts polled by Capital IQ expected $3.29. Operating revenue for the quarter ended Dec. 31 was $690.1 million, up from $576.2 million a year earlier. Analysts surveyed by Capital IQ estimated $662.6 million. MSCI said it has raised its quarterly dividend to $1.60 per share, up from $1.38 in the previous quarter. The higher dividend is payable on Feb. 29 to shareholders of record on Feb. 16.

MSCI’s Q4 Adjusted Earnings, Operating Revenue Increase Read Post »

CFRA Maintains Hold Opinion On Shares Of General Motors Company

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target by $4 to $38, based on a ’25 P/E of 4.5x, a steep but justified discount to historical averages. We increase our adjusted EPS estimates to $8.90 from $6.40 for ’24 and to $8.50 from $6.90 for ’25. GM posts Q4 adjusted EPS of $1.24 vs. $2.12 (-42%), 10 cents ahead of consensus. The beat was driven by a stronger-than-expected top line, as revenue fell 0.3% to $43.0B ($3.5B above consensus) on 3.3% higher sales volumes. GM introduced 2024 adjusted EPS guidance of $8.50-$9.50 (current consensus = $7.76), implying Y/Y growth of 17% at the midpoint versus the $7.68 earned in 2023. The guidance largely reflects an anticipated $1.45/sh. positive impact from the previously announced share repurchase plan, but was a positive

CFRA Maintains Hold Opinion On Shares Of General Motors Company Read Post »

Netflix, Inc. (NASDAQ: NFLX) Stock Analyst Ratings

Netflix, Inc. (NASDAQ: NFLX) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/30/2024 — Seaport Global Downgrades Buy → Neutral 01/26/2024 -2.66% Citigroup $500 → $555 Maintains Neutral 01/25/2024 -0.91% Goldman Sachs $500 → $565 Maintains Neutral 01/25/2024 5.23% DZ Bank → $600 Upgrades Hold → Buy 01/24/2024 -16.69% Barclays $375 → $475 Maintains Equal-Weight 01/24/2024 5.23% Morgan Stanley $550 → $600 Maintains Overweight 01/24/2024 -0.91% Goldman Sachs $500 → $565 Maintains Neutral 01/24/2024 11.89% BMO Capital $566 → $638 Maintains Outperform 01/24/2024 14% Wells Fargo $460 → $650 Maintains Overweight 01/24/2024 -0.03% UBS $560 → $570 Maintains Buy 01/24/2024 -3.54% Piper Sandler $475 → $550 Maintains Neutral 01/24/2024 4.35% Macquarie $410 → $595 Upgrades Neutral → Outperform 01/24/2024 7.86% Wedbush $525 → $615 Maintains Outperform 01/24/2024 -7.92% Deutsche Bank $460 → $525 Downgrades Buy → Hold 01/24/2024 1.72% Keybanc $545 →

Netflix, Inc. (NASDAQ: NFLX) Stock Analyst Ratings Read Post »

Uber Technologies, Inc. (NYSE:UBER) Stock Analyst Ratings

Uber Technologies, Inc. (NYSE:UBER) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/30/2024 9.1% B of A Securities $68 → $73 Maintains Buy 01/26/2024 1.63% Truist Securities $58 → $68 Maintains Buy 01/24/2024 -1.36% Gordon Haskett → $66 Downgrades Buy → Hold 01/22/2024 6.11% Needham $63 → $71 Maintains Buy 01/17/2024 15.08% Mizuho $63 → $77 Maintains Buy 01/16/2024 -5.84% Needham → $63 Reiterates Buy → Buy 01/12/2024 16.57% Goldman Sachs $59 → $78 Maintains Buy 01/11/2024 16.57% Goldman Sachs $59 → $78 Maintains Buy 01/09/2024 3.12% BMO Capital → $69 Initiates Coverage On → Outperform 12/29/2023 -7.34% Nomura $59 → $62 Downgrades Buy → Neutral 12/19/2023 4.62% Keybanc $61 → $70 Maintains Overweight 12/04/2023 12.09% Oppenheimer $65 → $75 Maintains Outperform 12/01/2023 -7.34% JMP Securities → $62 Reiterates Market Outperform → Market Outperform 11/30/2023 -5.84% Needham → $63 Reiterates Buy →

Uber Technologies, Inc. (NYSE:UBER) Stock Analyst Ratings Read Post »

Citigroup (NYSE:C) Stock Analyst Ratings

Citigroup (NYSE:C) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/30/2024 18.63% Morgan Stanley $46 → $65 Upgrades Underweight → Overweight 01/16/2024 69.74% Oppenheimer $85 → $93 Maintains Outperform 01/16/2024 2.21% Piper Sandler $53 → $56 Maintains Neutral 01/10/2024 — BMO Capital Downgrades Outperform → Market Perform 01/09/2024 11.33% HSBC → $61 Upgrades Hold → Buy 01/03/2024 5.86% Wolfe Research → $58 Upgrades Peer Perform → Outperform 01/02/2024 14.98% Barclays $59 → $63 Maintains Equal-Weight 12/19/2023 -5.09% Goldman Sachs $47 → $52 Maintains Neutral 12/01/2023 -14.22% Goldman Sachs $41 → $47 Maintains Neutral 11/16/2023 55.14% Oppenheimer $82 → $85 Maintains Outperform 10/16/2023 -17.87% Piper Sandler $47 → $45 Maintains Neutral 10/16/2023 20.46% BMO Capital $61 → $66 Maintains Outperform 10/16/2023 49.66% Oppenheimer $81 → $82 Maintains Outperform 10/03/2023 -21.52% Morgan Stanley $45 → $43 Maintains Underweight 10/02/2023 -25.17% Goldman Sachs $47 →

Citigroup (NYSE:C) Stock Analyst Ratings Read Post »

Goldman Sachs (NYSE:GS) Stock Analyst Ratings

Goldman Sachs (NYSE:GS) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/30/2024 17.39% Morgan Stanley $333 → $449 Upgrades Equal-Weight → Overweight 01/18/2024 -5.88% BMO Capital $357 → $360 Maintains Market Perform 01/17/2024 15.03% JMP Securities → $440 Reiterates Market Outperform → Market Outperform 01/17/2024 28.37% Oppenheimer $481 → $491 Maintains Outperform 01/09/2024 15.03% UBS $382 → $440 Maintains Buy 01/09/2024 10.07% JP Morgan $398 → $421 Maintains Overweight 01/02/2024 28.89% Barclays $437 → $493 Maintains Overweight 12/04/2023 -12.94% Morgan Stanley $329 → $333 Maintains Equal-Weight 11/16/2023 22.35% Oppenheimer $447 → $468 Maintains Outperform 10/19/2023 16.86% Oppenheimer $450 → $447 Maintains Outperform 10/18/2023 15.03% JMP Securities → $440 Reiterates Market Outperform → Market Outperform 10/10/2023 15.03% JMP Securities $450 → $440 Maintains Market Outperform 10/03/2023 -13.99% Morgan Stanley $347 → $329 Maintains Equal-Weight 09/26/2023 17.65% Oppenheimer $461 → $450 Maintains Outperform 09/21/2023

Goldman Sachs (NYSE:GS) Stock Analyst Ratings Read Post »

Pfizer’s Non-Covid Revenue Grew In 4Q And 2023

Pfizer’s 4Q revenue dropped 41% to $14.25B, below analyst forecasts, due to an expected decline in demand for its Covid-19 vaccine Comirnaty and Covid-19 treatment Paxlovid. Excluding those products, revenue was up 7% operationally, driven by new product launches and in-line product growth. The same trend followed for the full year, with 2023 revenue falling 42% overall but being up 8% when excluding Covid products. Pfizer is targeting operational revenue growth of 8% to 10% in 2024 when excluding Comirnaty and Paxlovid, as well as its Seagen subsidiary, though the company still expects to see about $8B in annual revenue from the two Covid products.

Pfizer’s Non-Covid Revenue Grew In 4Q And 2023 Read Post »

Scroll to Top